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Summary Thymic epithelial tumours are broadly classified into thymomas and thymic carcinomas. Although both tumours occasionally show
invasive growth, they exhibit different clinical and biological findings. The oncogene and anti-oncogene in thymic epithelial tumours have not
been evaluated fully. We investigated the expression of p53 protein by immunohistochemical analysis using the anti-p53 polyclonal antibody
(CM-1) in 17 thymomas and 19 thymic carcinomas. We also examined p53 gene (exon 5-8) mutation in 18 thymic carcinomas by using
polymerase chain reaction-single-strand conformation polymorphism methods and direct sequencing. Of the thymoma cases, only one
invasive thymoma showed focal nuclear staining. Fourteen of the 19 thymic carcinomas (74%) showed nuclear staining. Point mutations of
the p53gene were recognized in only 2 of the 18 thymic carcinomas (11%). One was the mutation C to T transition in the first letter of codon
222 in exon 6, which results in the amino acid substitution from proline to serine. Another was a silent mutation. p53 protein accumulation is
highly frequent in thymic carcinomas but not in thymomas, and gene mutation is uncommon in thymic carcinomas.
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Thymic epithelial tumours are broadly classified into thymomas
and thymic carcinomas. Thymomas exhibit cytologically bland
neoplastic epithelial cells and a variable number ofnon-neoplastic
T-lymphocytes. Thymomas show zonal differentiation, i.e. cortex
and medulla elements, which is similar to the normal thymus to
some extent (Kodama et al, 1986; Sato et al, 1986; Kondo et al,
1990). Thymomas occasionally show invasive growth and pleural
seeding, but lymphogenous or haematogenous metastasis is rare.
In contrast, thymic carcinomas do not show zonal differentiation,
and their epithelial cells show obvious cytological atypia and are
not able to attract and retain immature T-lymphocytes (Kodama et
al, 1986; Sato et al, 1986; Kondo et al, 1990). Thymic carcinomas
grow invasively and frequently show lymphogenous or haemato-
genous metastasis. Recent studies have disclosed that thymic
carcinomas are different from thymomas in some biological
characteristics, i.e. nuclear area, mean nuclear DNA content, DNA
histogram pattern and ploidy pattern (Asamura et al, 1988).
In human cancers, accumulation of the p53 protein is probably
the most common abnormality (Bartek et al, 1991). Missense
mutation ofthep53 gene or some oncoproteins binding to the p53
protein prolongs the half-life of the p53 protein and leads to the
accumulation ofp53 protein. It also abrogates the ability ofnormal
p53, which suppresses tumour growth (Kuerbitz et al, 1992;
Takahashi et al, 1992; Jiang et al, 1993). This may be an important
step in the complex process ofcarcinogenesis in human cancer.
To clarify the relationship between the tumour-suppressor gene
p53 and thymic epithelial tumours, we investigated the expression
of p53 protein in thymomas and thymic carcinomas, and the
mutation ofthep53 gene in thymic carcinomas.
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MATERIALS AND METHODS
Materials
Tumour tissues were obtained from 17 thymoma and 19 thymic
carcinoma patients who had undergone surgery or biopsy at
the Second Department of Surgery, School of Medicine, the
University of Tokushima, between 1980 and 1994. All tissues
were fixed in formalin and embedded in paraffin wax.
The patients with thymoma included four men and 13 women,
whose ages ranged from 29 to 80 years (average 54.8 years). Two
patients had myasthenia gravis. The clinical stage ofthymoma was
determined according to the criteriaofMasaoka et al (1981). Eight
of the 17 thymomas were non-invasive tumours (clinical stage I).
The other nine thymomas were invasive tumours (clinical stage II,
III, or IV) (Table 1). The patients with thymic carcinoma included
12 men and seven women, whose ages ranged from 47 to 86 years
(average 63.6 years). They had no myasthenia gravis. The histo-
logical diagnosis of the tumours was squamous cell carcinoma in
13, spindle cell carcinoma in two, undifferentiated carcinoma in
two, adenosquamous cell carcinoma in one and small-cell carci-
noma in one (Table 1). The clinical stage ofthymic carcinoma was
determined according to the criteria ofMasaoka et al (1981).
Wild-type p53 gene from a normal lung tissue was used as a
negative control in the polymerase chain reaction-single-strand
conformation polymorphism (PCR-SSCP) analysis. Five normal
lung and 17 lung carcinoma tissues (seven lung carcinoma tissues
with missense mutation in the p53 gene, one with nonsense muta-
tion and nine with wild-type p53 gene, which have been reported
previously; Kondo et al, 1992) were used as a control in the
immunohistochemical staining for p53 protein.
Immunohistochemical staining for p53
Five-micron-thick paraffin-embedded sections of each thymoma
and thymic carcinoma were cut, deparaffinized and rehydrated
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Table 1 Clinical findings in 36 thymic epithelial tumours
Thymic carcinoma Thymoma
(n=19) (n=17)
Age(years) 63.6 ± 10.97 54.8 ± 15.69
(47-86) (29-80)
Sex
Male 12 4
Female 7 13
Histology
Sq 13 Lym 3
Sp 2 Mix 8
Ud 2 Ep 6
Sm 1
Ad 1
Disease stage
0 8
11 2 3
III 6 3
IVa 2 2
lVb 9 1
Sq, squamous cell carcinoma; Sp, spindle cell carcinoma; Ud,
undifferentiated carcinoma; Sm, small-cell carcinoma; Ad, adenosquamous
cell carcinoma; Lym, lymphocyte-predominant type; Mix, mixed type; Ep,
epithelial-predominant type.
through xylene and graded alcohols. For antigen retrieval, the
sections were placed in a Coplin jar containing 0.01 M citrate
buffer (pH 6.0) and microwaved at 5-min intervals for a total
15 min at maximal level in a household microwave oven (Shi
et al, 1991). After heating, the Coplin jar was removed from the
microwave oven and allowed to cool. Endogenous peroxidase
was inhibited with 3% hydrogen peroxide, and non-specific
binding was blocked with bovine serum albumin. Sections were
incubated with anti-p53 polyclonal antibody, CM-1 (Novocastra
Laboratories, Newcastle, UK) (Midgley et al, 1992) diluted 1:1500
(Fisher et al, 1994) at room temperature for 60 min. After washing
with Tris-buffered saline (TBS, pH 7.6), the sections were incu-
bated for 15 min with biotinylated anti-rabbit and anti-mouse
immunoglobulins and incubated with streptavidin conjugated to
horseradish peroxidase for 15 min using and LSAB kit (Dako,
Carpinteria, CA, USA). The peroxidase reaction was developed
with a 0.05% solution of diaminobenzidine tetrahydrochloride.
Sections were counterstained with haematoxylin. Under light
microscopy, we evaluated at least 1000 tumour cells per high-
power field. Samples that revealed nuclear staining in more than
10% ofthe tumour cells were classified as 'positive.' In the evalu-
ation of the p53 protein, we paid no regard to the intensity of the
staining because it is dependent on the fixative methods, which
may vary among specimens.
Preparation of DNA
We used paraffin-embedded sections in which the tumour occu-
pied more than 70% of the tissue. Five 10-,um sections were cut
and placed in an Eppendorf reaction tube (1.5 ml). These sections
were deparaffinized through xylene and graded alcohols. To each
of the samples, 400gl of lysis buffer containing 150 mm sodium
chloride, 15 mm sodium citrate, 1% sodium dodecyl sulphate
(SDS) and 0.1 mg ml' of proteinase K was added. The samples
were vigorously shaken for 24 h at48°C. Afterphenol-chloroform
extraction, DNAs were precipitated with cold ethanol for 20 min at
-80°C. After centrifugation, the pellets were dried and resus-
pended in 5-50 ,ul ofdistilled water.
PCR-SSCP analysis
Exons 5-8 of the p53 gene were investigated by PCR-SSCP
methods (Hayashi, 1992). The primer pairs were labelled with
[,y-32P]dATP as described previously (Sasa et al, 1993). For ampli-
fication, 0.1 ,gg oftumour DNA was incubated in a total volume of
10 ,l ofPCR buffer containing 20 mm Tris-HCl, 50 mm potassium
chloride, 2 mm magnesium chloride, 200 gM deoxynucleotide
triphosphate, 1 ,UM each of 5' and 3' oligonucleotide primers and
0.125 units of DNA Polymerase (Takara Biomedicals, Shiga,
Japan). The mixture was overlaid with mineral oil and then ampli-
fied. Templates were denatured for 3 min at 95°C, followed by 35
temperature cycles that consisted of 30 s at 94°C, 30 s at 55°C and
60 s at 72°C.
The primer sequences are listed below.
Exon 5 5' side: TTCCTCTTCCTGCAGTAC
3' side: GCCCCAGCTGCTCACCATCG
Exon 6 5' side: CCTCACTGATTGCTCTTAGG
3' side: ACCCCAGTTGCAAACCAGAC
Exon 7 5' side: CTCCTAGGTTGGCTCTGACT
3' side: CAAGTGGCTCCTGACCTGGA
Exon 8 5' side: CCTATCCTGAGTAGTGGTAA
3' side: GTCCTGCTTGCTTACCTCGC
The amplified and labelled DNA fragments thus obtained were
subjected to electrophoresis at 40 W for 1-4 h in a 6% non-
denatured polyacrylamide gel, with or without 10% glycerol, at
room temperature. The gel was dried on 3 MM paper (Whatman,
Maidstone, UK) and exposed to radiographic film at -80°C for 1
to 12 h, with an intensifying screen.
Direct sequencing
The extra bands revealed by SSCP analysis were excised. The
DNAs were extracted from the extra bands and amplified by PCR.
The PCR products were purified using a Mermaid Kit (BIO 101,
La Jolla, CA, USA) and directly sequenced using the Taquence
Cycle-Sequencing Kit (Biochemical, Cleveland, OH, USA). The
PCR products amplified separately from the same sample were
also directly sequenced at least twice.
RESULTS
Immunohistochemical analysis
Normallungs andlung carcinomas
We analysed p53 expression in the 17 lung carcinomas and five
normal lung tissues with and without antigen retrieval by
microwave treatment.
Two ofthe nine lung carcinomas with wild-typep53 (22%) and
four of the seven lung carcinomas with p53 missense mutation
(57%) stained positively in immunohistochemical analysis without
microwave treatment. In immunohistochemical analysis with
microwave treatment, three ofthe nine lung carcinomas with wild-
typep53 (33%) and all seven lung carcinomas with p53 missense
mutation (100%) stained positively (Figure IA).
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Figure 1 The staining patterns in p53 immunohistochemistry with antibody CM-1. (A) Lung carcinoma with p53 mutation shows diffuse nuclear staining.
(B) Invasive thymoma with atypia shows expression of p53 protein (arrows) on the border of the tumour. (C) Nuclear staining of a majority of nuclei is present
in thymic carcinoma. (D) Nuclear staining is not shown in thymic carcinoma. Bar = 50 pim
The p53 expression detected in the lung carcinomas by
immunohistochemical analysis with microwave treatment was
significantly correlated with the p53 gene missense mutation
(P < 0.05) by Fisher's exact probability test.
The one lung carcinoma withp53 nonsense mutation and all five
normal lungs showed an absence of nuclear staining in the
immunohistochemical analysis both with and without microwave
treatment.
Thymomas
We analysed the p53 expression in the eight non-invasive
thymomas and the nine invasive thymomas. When we did not
perform the microwave treatment, no thymomas were stained posi-
tively. Even with the microwave treatment, only one of the 17
thymomas was positive for p53 expression. p53 was focally
stained on the border of the tumour (Figure 1B). This case was
diagnosed as 'invasive thymoma, atypia type combined thymic
carcinoma'.
Thymic carcinomas
The numbers of p53-positive cases among the 19 thymic carci-
nomas with and without microwave treatment were 14 (74%) and
3 (16%) respectively (Figure IC and D). The positive rate of
staining was 100% (two out of two) in stage II, 67% (four out of
six) in stage III and 73% (8 out of 11) in stage IV. The expression
of p53 protein in the thymic carcinoma tissues was not correlated
with the clinical stage. Five cases showed nuclear positive staining
in more than 50% of the tumour cells.
p53 gene mutation in thymic carcinomas
As it is generally reported that the expression of p53 protein is
correlated with missense mutations of the p53 gene, we examined
p53 gene mutations in the 18 thymic carcinomas by PCR-SSCP
and direct sequencing methods. Exons 5-8 of the p53 gene were
amplified by PCR, and the PCR products were analysed by SSCP.
The DNAs of 2 of the 18 thymic carcinomas showed different
mobilities from those of the normal lung in the SSCP analysis.
Each of these two samples gave four bands: two with the same
mobilities as those of the normal lung, corresponding to the two
strands of the normal allele, and two other bands with different
mobilities, representing the two strands of an aberrant allele
(Figure 2A). To confirm the mutation, we performed direct
sequencing.
In one case, a sequencing ladder of the variant bands demon-
strated the mutation CCG to TCG transition in codon 222 in exon
6, which results in the amino acid substitution from proline to
serine (Figure 2B). This sample showed nuclear staining for p53
protein in the immunohistochemical study with microwave treat-
ment. In the other case, a sequencing ladder of the variant bands
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Figure 2 (A) Results of PCR-SSCP analysis for exon 6. N is a wild-type
p53 gene from normal lung; others are from thymic carcinomacs. Lane 10
shows bands with different mobility (arrows) from normal bands. (B) Direct
sequencing of the PCR product from lane 10, which shows a mobility shift,
demonstrated the mutation C to T transition in the first letter of codon 222 in
exon 6, which results in the amino acid substitution from proline to serine
revealed the mutation CAC to CAT transition in codon 178 in exon
5, which was a silent mutation (data not shown); this case did not
show nuclear positive staining forp53 protein in the immunohisto-
chemical study with and without microwave treatment.
DISCUSSION
Thymic carcinoma has long been the source of controversy
because of the lack of agreement regarding its definition and
proper criteria for diagnosis. Since Shimosato et al (1977) reported
eight cases of primary squamous cell carcinoma of the thymus,
there have been many reports of thymic carcinoma (Wick et al,
1982; Truong et al, 1990; Suster and Rosai, 1991). Thymic epithe-
lial tumours are broadly classified into thymomas and thymic
carcinomas. We define thymic carcinoma as a neoplasm ofthymic
epithelial cells that exhibits cytological atypia and is not associated
with non-neoplastic immature T-lymphocytes, in accord with
Shimosato (1994).
It is reported that some fixation methods weaken the anti-
genicity of the p53 protein (Fisher et al, 1994). In the present
study's immunohistochemical analysis without antigen retrieval
Figure 3 The immunohistochemical expression of p53 protein in thymic
epithelial tumours with microwave treatment. *Cases in which more than 50%
of tumour cells were stained positively
by microwave, p53 protein expression in all samples was rare and
weak compared with that in the analysis with antigen retrieval.
Although the mechanism ofrecovering antigenicity by microwave
heating is not clear, it is possible that the cross-linking ofproteins
causedby formaldehyde is altered by microwaves (Shi et al, 1991).
We conclude that the results of our immunohistochemical analysis
with antigen retrieval by microwave are more reliable than those
without antigen retrieval.
We examined the p53 protein expression in the thymic epithelial
tumours by immunohistochemical analysis using the polyclonal
antibody (CM-1) with antigen retrieval by microwave. Only one of
the 17 thymomas (6%) was stained positively by p53 antibody. In
contrast, 14 ofthe 19 thymic carcinomas (74%) were stained posi-
tively (Figure 3). Tateyama et al (1995) reported that 57% of the
thymomas and 100% of the thymic carcinomas examined showed
p53 expression by an anti-p53 antibody, DO-7. None of 21
thymomas and 4 of 13 thymic carcinomas showed nuclear positive
staining in more than 50% of the tumour cells. Hayashi et al
(1995) demonstrated that the positive rate of p53 immunoreac-
tivity by an anti-p53 antibody (BP53-12) was 42% in non-invasive
thymomas, 82.4% in malignant thymomas (category I) and 83.3%
in malignant thymomas (category II) according to the classifica-
tion by Rosai (Suster and Rosai, 1991). Chen et al (1996) reported
that three of five (60%) non-invasive thymomas, 8 of 18 (44%)
invasive thymomas and 12 of 17 (71%) thymic carcinomas were
positive for p53 immunostaining by an anti-p53 antibody,
PAbl801. Although the immunoreactivity of thymic carcinoma
in the present study was similar to that of their studies, the
immunoreactivity ofthymoma in the present study was lower than
that oftheir studies. The difference may be due to the sensitivity of
the anti-p53 protein antibody used. For example, DO-7 (which
Tateyama et al (1995) used) or PAb1801 (which Chen et al (1996)
used) is more sensitive than CM-I for the immunohistochemical
analysis of the p53 protein (Friedrichs et al, 1993; Baas et al,
1994). The sensitivity of the anti-p53 protein antibody used may
make the difference in p53 expression between thymomas and
thymic carcinomas unclear. Gilhus et al (1995) reported that none
ofthe cells in the sections from 24 thymomas were stained for p53
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protein with any ofthe three antibodies DO-7, p240 and PAbl801.
Gilhus's result was almost identical to our result. These studies
support our finding that the thymic carcinomas showed a higher
p53-positive rate than that ofthe thymomas. The p53 protein accu-
mulation interferes with the ability of wild-type p53 to inhibit
tumour growth (Kuerbitz et al, 1992; Jiang et al, 1993). According
to this principle, thymic carcinomas have a tendency to be more
proliferative than thymomas.
It is very interesting that the single thymoma case positive for
p53 protein in the present study showed characteristics of both
thymomas and thymic carcinomas. The tumour showed marked
nuclear atypia accompanied by immature T-lymphocytic infiltra-
tion (CDla antibody-positive lymphocytes). Similar cases were
reported by Shimosato et al (1994) and Kirchner et al (1992).
Shimosato (1994) diagnosed these tumours as 'invasive thymoma,
atypical type', and Kirchner diagnosed them as 'well-differentiated
thymic carcinoma' (Kirchner et al, 1992).
It has been reported that p53 protein accumulation is caused by
missense mutation ofthep53 gene or by interaction ofp53 protein
with some oncoproteins. In order to clarify the cause of p53
expression in thymic carcinomas, we examined 18 thymic carci-
nomas for mutation in exons 5-8 of the p53 gene by PCR-SSCP
and direct sequence methods. The missense mutation was found in
only one case of the 18 thymic carcinomas. This discrepancy
between gene mutation and accumulation of the p53 protein has
been reported in some types oflymphomas. In non-HTLV-I associ-
ated post-thymic T-cell lymphoma, p53 protein overexpression
was detected in 17 of34 cases, whilep53 mutations were detected
in only 3 (17.6%) of these 17 cases (Villuendas et al, 1993). This
discrepancy has also been reported in non-Hodgkin's lymphomas
and anaplastic large-cell lymphoma (Cesarman et al, 1993;
Matsushima et al, 1994). Although there is the possibility that the
mutation may be in a portion ofthe gene not evaluated, mutations
ofthe region other than at exons 5-8 are infrequent in the previous
reports. Hollstein et al (1991) demonstrated that the majority ofthe
missense mutations are at codons (exons 5-8) corresponding to
amino acids conserved in diverse types of human cancer. We
suggest that the expression of p53 protein in thymic carcinomas
might be due to interactions with oncoproteins rather than
missense mutations, and that a certain oncoprotein might interact
with p53 protein in thymic carcinomas and lead to the stabilization
ofwild-type p53 protein.
Murine double minute 2 (MDM2) protein is known to bind to
p53 protein and inhibit p53-mediated transactivation (Momand et
al, 1992). We examined the expression ofMDM2 using the mono-
clonal antibody lB10 (Novocastra Laboratories, Newcastle, UK)
(Otto et al, 1993) for MDM2 protein in the thymic carcinoma. In
only one of ten thymic carcinomas, the nucleus was stained
diffusely (data not shown). The MDM2 protein expression in the
thymic carcinomas seems not to relate to p53 protein expression.
Takeyama et al (1995) reported that all tumours (eight
thymomas and two thymic carcinomas) that they examined had
missense mutations in the p53 gene, and that three of these
tumours were focally stained by anti-p53 antibody (a positive rate
of <10%). This is a surprisingly high rate compared with other
human cancers. Weirich et al (1996) reported two (13%) missense
mutations and two (13%) silent mutation cases among 16 thymic
carcinomas and no mutations in 28 thymomas detected by PCR-
SSCP analysis and sequencing methods. Weirich's results are
similar to ours. The sensitivity of PCR-SSCP for detecting point
mutations is more than 89% for 300- to 400-bp fragments, and the
specificity is 100% (Hayashi, 1992). We believe that p53 gene
mutations in thymic epithelial tumours are rare.
The overexpression of the p53 protein in lung cancer in the
present study was almost as frequent as that in the thymic carci-
nomas. Most of the lung cancers with p53 protein expression had
missense mutations. In contrast, few thymic carcinomas with p53
protein expression had missense mutations. p53 protein expression
without missense mutation might be one of the differential
diagnostic factors between thymic carcinoma and lung cancer.
In conclusion, p53 protein accumulation was highly frequent in
the thymic carcinomas but not in the thymomas, while gene muta-
tion was uncommon in the thymic carcinomas. We suggest that the
accumulation of p53 protein may correlate with the difference
in the malignant potential between thymic carcinomas and
thymomas. This characteristic may be one ofthe differential diag-
nostic factors between thymic carcinoma and lung cancer.
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